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Abstract
Applications of nanotechnology and material sciences emerge in the development 
of various novel drug delivery systems that have been proven as promising clinically. 
Among these, liposomes, noisome, polymeric carriers and lipid-based delivery sys-
tem were extensively explored and enter into clinical trials and clinical applications. 
However, each system has its own pros and cons in term of different physicochemi-
cal, pharmacokinetics and therapeutics aspects. Lipid-polymer hybrid carriers merge 
the potential benefit of these structural components and can be prepared by dif-
ferent approaches to improve the therapeutic outcomes. In this chapter, we provide 
the useful insight about the lipid-polymer hybrid nanoparticles (LPHNPs) that can 
be prepared by using the different structural components including the synthetic 
and natural polymers and lipids. Among these, we also explain the various methods 
to prepare the LPHNPs with various desired characteristics. Finally, the various 
therapeutic and clinical applications have been presented briefly.
Keywords: lipid-polymer hybrid, nanoparticles, drug delivery, targeted release
1. Introduction
The advances in the field of nanotechnology and the material sciences have been 
open a new horizon for the development of various drug delivery systems (DDS) 
for the effective and efficient delivery of therapeutic and diagnostic agents [1]. 
During last few decades, many new DDS have been explored in term of their struc-
tural components and medical applications. These systems enhance the application 
of novel approaches toward the translational medicines by improving the prepara-
tion techniques and combing the natural and synthetic polymers and materials 
[2]. Formulation of these DDS helps to encapsulate a variety of chemotherapeutic 
agents, vaccines, proteins, antibodies, nucleic acids and diagnostic agents [3]. These 
agents might be encapsulated inside the core of NPs or might be adsorbed on the 
surface individually or in combination. These formulations enhance the pharmaco-
kinetic and pharmacodynamics properties of the NPs by increasing the solubility, 
dispersion, permeability and overall bioavailability of the formulation. The release 
of the drug might be controlled passively or actively through various stimuli such as 
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temperature, and pH [4]. All these factors results in the higher concentration of the 
entrapped drug that reached the systemic circulation that helps to attain the mean 
effective concentration without producing any toxic effects [5].
Among these DDS, polymeric nanoparticles (NPs), liposomes, niosomes, 
dendrimers and porous silicon NPs have been extensively employed in the pharma-
ceutical delivery. Polymeric NPs have versatility in term of their chemical composi-
tion and applications. Large type of chemical material based NPs were formulated 
such as polymeric NPs, Porous silicon NPs, Carbon nanotubes, Graphene NPs and 
quantum dot. All these DDS have their own pros and cons in term of drug loading, 
encapsulation, release and applicability [6]. Furthermore, all these DDS were deco-
rated with different chemical reagents and ligands to impart the desired character-
istics through modifying the physicochemical properties of the NPs including (1) 
enhanced means residence time and improved stability, (2) external stimuli driven 
drug release, (3) controlled and targeted delivery of various chemotherapeutics 
agents and (4) administration of various theranostic agents [7].
These nanocarriers have been explored due to their extensive potential applica-
tions and excellent in vitro performances, but these NPs still have poor in vivo 
properties in term of their poor solubility in various body fluids, rapid uptake and 
excretion by the body defense system, poor penetration among the various biologi-
cal membranes and body tissues, uncontrolled fluctuations in the plasma levels of 
the active therapeutic components and dose related toxicity issues [8, 9].
The most important domains of these nanocarriers include the polymeric DDS 
and the lipid based vesicular systems. The polymeric DDS provide the variety in 
term of their structural materials and chemical composition [6]. Different polymers 
include from the synthetic and natural sources have been employed for the medical 
applications. These DDS include the polymeric NPs, mesoporous silicon NPs, metal 
coated NPs, inorganic NPs, dendrimers and the carbon nanotubes [10]. Vesicular 
DDS include the liposome and noisome. These were defined as the single and the 
multilayer lipid vesicles while the niosomes were made up of nonionic surfactants 
instead of the phospholipids [11]. These novel systems provide excellent compat-
ibility with other ingredients, higher and simultaneous encapsulation of the hydro-
philic and lyophilic therapeutic moieties and due to lipid nature it provide better 
pharmacokinetic profiles that might lead to improved therapeutic response of the 
encapsulated drug. But still this system might suffer from some draw back in term 
of drug leakage, stability problems and difficulty in the scale up of the process [12].
The above-mentioned problems associated with these DDS including liposomes 
and polymeric nanoparticles can be overcome by merging their structural components 
by formulating the lipid-polymer hybrid nanoparticles (LPHNPs). These NPs combine 
the potential benefits and reduce the different drawbacks of all the individual struc-
tural components [13]. These hybrid particles might be produced in different morphol-
ogies including the core shell and matrix type LPHNPs. The core or the central material 
may be encapsulated in single and/or multiple layers of the lipid on the polymeric core 
materials that also provide the site for the surface modification with different targeting 
moieties and ligands that help to induce the desired characteristics in the DDS [14].
In this chapter, the different structural components such as lipids and poly-
mers were explained along with the different formulation methods to prepare the 
LPHNPs along with various process parameters and their pros and cons.
2. Structural components and their arrangement mechanism
The core and the shell materials might include different polymeric materials, 
oils, metal oxides, organic and inorganic compound from the natural and synthetic 
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sources that successfully employed for the fabrication of the NPs. These systems 
have been composed of following major layers and components given as fellows
i. The inner most layer consist of different polymers, organic and inorganic 
materials that act as a core material. These core materials might be coated 
with other agents or may form a matrix structure that then functionalized by 
using the different targeting moieties. These cores of the NPs might encapsu-
late the hydrophilic or hydrophobic drugs [15].
ii. The second layer of these hybrid NPs is fabricated with the natural or 
derived lipid that impart the desired pharmacokinetic properties to the 
DDS. This layer encapsulates the central polymeric core and enhances the 
compatibility with the biological system. While it also act as a permeability 
control barrier that limit the release of loaded therapeutic agent as a function 
of water penetration [16].
iii. The third layer is composed of either lipid or polymer-conjugate that help in 
the functionalization or surface decoration of the NPs to provide the desired 
therapeutic of pharmacokinetic effects in term of target specific release and 
improved retention time of the NPs in the biological system [17].
The mechanism of the arrangement in different layers and their compilation 
with each other might need further investigation. However, different mechanisms 
Figure 1. 
Schematic diagram of the lipid-polymer hybrid nanoparticles.
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explored indicate that the arrangement and fusion process are based on the 
method of preparation (that were discussed in the next section). In the two-step 
conventional method, the layer might be due to formation of lipid by layer that 
get adhere to the core particle that followed by the integration due to hydrophilic 
and hydrophobic interaction among the lipid and polymer component. However, 
in the single-step method, the most investigated and revealed mechanism is the 
precipitation of the lipid component on the polymeric core material. Some newer 
techniques might also involve the self-assembling of these structural components 
(Figure 1) [18].
3. Method of preparation
Various formulation methods have been designed and employed for the prepa-
ration of LPHNPs based on the chemical and physical nature of the structural 
components and the desired therapeutic purpose or outcome. These hybrid DDS 
include the lipid-polymer, lipid metal, polymer-inorganic hybrid, metal (Gold, 
Silver or Iron) along with polymer hybrid NPs have investigated and employed 
for the clinical use. Conventionally, two different approaches have been investi-
gated including the two-step and single-step processes. First approach employed 
the mixing of the inner core and the outer layers to prepare the LPHNPs. While 
the single-step approach the lipid and polymer that are assembled using the 
different mechanisms to form the LPHNPs that overcome the drawback of 
individual components.
3.1 Two-step conventional method
Two-step method was the most primitive and frequent method applied for 
the preparation of different hybrid nanoparticles and other DDS. In the method, 
the different layers comprise of structurally, different components were sepa-
rately fabricated and then co incubated to make a complete particle by using the 
various approaches including the adsorption, self-assembling and encapsula-
tion. The core and shell morphology might be obtained and the various hybrid 
nanoparticles were obtained by using the sonication [19], solvent emulsification, 
solvent evaporation [13], nanoprecipitation [20], extrusion, high speed homog-
enizers and other techniques. However, the selection of the method is based on 
the physicochemical properties of the loaded drug, size of the core particle and 
the desired properties that you want to introduce in the NP formulation [18]. 
For example, the single-step method has been chosen when the encapsulating 
materials are miscible with the coating substance and soluble in the organic 
solvent [21].
This method involves multiple preparatory steps to prepare the polymeric core 
materials and then the lipid vesicles by the different techniques. The polymeric 
core material might be prepared by dissolving the polymer in a suitable solvent and 
then precipitated into some nonsolvent phase. Finally, the both components are 
co-incubated and mixed under gentle stirring for certain time period to allow them 
to get assembled into lipid-polymer hybrid particles [22, 23]. The mixing may be 
carried out by vortexing, thin film hydration, probe sonication or extrusion pro-
cesses so that the final LPHNPs were obtained. These processes actually provide the 
energy for the mixing, layering or adsorption of the outer coating material on the 
polymeric core material that might be strengthen by the electrostatic forces among 
these structural components.
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3.2 Modified two-step method
Different modifications have been suggested in the conventional two-step pro-
cess for the fabrication of the LPHNPs. These modifications might include the use 
spray drying and lithographic molding along with the freeze drying [24]. The inner 
central core of the NPs have been prepared with the process that further suspended 
or dispersed in any suitable organic solvent containing the different structural 
components of the LPHNPs [2]. Different studies indicate the formulation of 
LPHNPs loaded with various antibiotics agents including levofloxacin, ciprofloxa-
cin and isoniazid in the form of freeze dried powders for the inhalation therapy 
that were entrapped in the mono or multiple layers of the lipid shell. The coating of 
the lipid might provide the core shell morphology to the NPs. This modification in 
the preparation of the NPs added advantage in term of better inhalation efficiency 
and greater control on the overall average particle size of the LPHNPs relative to the 
conventional method [25]. The nanoparticles and hybrid microfiber fabrication are 
the some other examples that utilized the polyglutamic acid, poly lysine and various 
grade of PLG and PLA using the freeze-drying method [26, 27].
3.3 Single-step preparation method
The poor entrapment and easy leakage of the drug from the polymeric core of 
the LPHNPs prepared by the conventional two-step methods urged the develop-
ment of some newer methods that overcome these shortcomings and enhance the 
therapeutic efficiency of the prepared formulation [14, 28]. The development of 
single-step method provides the way to control the particle size, PDI, uniformity of 
the structural components. It also overcomes the variability in different batches and 
other properties of the LPHNPs in term of their physicochemical properties and 
stability. The method involves the single preparatory step that considers the mixing 
of two different phases containing the lipid and polymer in each of the given phase. 
The mixing process followed by the self-assembling of the structural components 
that either make the matrix or core shell morphology [29].
Various techniques in the single-step preparation method might include the 
single or double emulsification method, sonication technique, nanoprecipitation, 
solvent evaporation method and solvent diffusion method.
4. Biomedical applications
LPNs have been prepared for efficient encapsulation and delivery of the wide 
range of therapeutic agents either alone or in combinations. LPNs have wide range 
of applications in cancer therapy and delivery of protein based therapeutic agents, 
i.e., small interfering RNA, nucleic acid and genes delivery etc. Additionally, LPNs 
can be used for oral drug delivery of many drugs [46]. LPN has wide range of 
applications in gene and DNA delivery, vaccines and diagnostic imaging agents as 
shown in Figure 2 [2].
4.1 Cancer therapy
Doxorubicin loaded polymer-lipid hybrid nanoparticles (Dox-PLN) were 
designed and injected intratumorally in mice. At a dose of 0.1 and 0.2 mg, 70 and 
100% tumor growth delay was observed, respectively. Dox-PLN treated mice have 
not shown any sign of toxicity and only 2 mice out of 15 exhibited transient fur 
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Type of 
hybrid 
nanoparticles
Structural components Physicochemical properties Biological 
properties
Application Reference
Size (nm) Zeta potential Entrapment 
efficiency
Lipid-polymer 
hybrid
Paclitaxel
PLGA
Soybean lecithin
DSPE-PEG (conjugated with folic acid)
186.9 ± 8.52 −29.5 ± 2.0 81.34 ± 3.41 T1/2 18.08
AUC 0-∞ 109.21
MRT 30.06
Brain targeting 
in glioblastoma 
multiform
[1]
Lipid-polymer 
hybrid
Melatonin
PLA
DDAB
CTAB
180–218 +15.4 to −36.1 90.35 N/A Ophthalmic 
delivery
[2]
PLGA
DOX in polymeric core and Sorafenib in 
lipidic core
β-cyclodextrin
Dipalmitoyl glycerol phophocholine 
(DPPC)
Distearoyl glycerol 
phosphoethanolamine (DSPE)
PEG
85.1
PDI 0.103
Sustained release 
for 21 days
Colon cancer [4]
Lipid-polymer 
hybrid
Gemcitabine, hypoxia-inducible factor 
1α, ε-polylysine co-polymer, PLGA, 
mPEG, Lecithin, double emulsion 
method and ultrasound assisted 
self-assembly
141.8 −34 42 Pancreatic 
cancer
[7]
Lipid-polymer 
hybrid
Budesonide, PLGA, 
dioleoyltrimethylammonium propane 
(DOTAP), double emulsion solvent 
evaporation method
PDI 0.09–0.14, 
136–169 nm
−3 to 54 20–36 and 
27–80
Chronic 
obstructive 
pulmonary 
disease (COPD)
[13]
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Type of 
hybrid 
nanoparticles
Structural components Physicochemical properties Biological 
properties
Application Reference
Size (nm) Zeta potential Entrapment 
efficiency
Lipid-polymer 
hybrid
Dextran, bovine serum albumin (BSA), 
astaxanthin, prepared through organic 
solvent free homogenization and 
sonication technique, Precirol® ATO 5 
(glyceryl palmitostearate)
139–180 nm, PDI 
0.199
70% 40% release in SGF 
and 50% in SIF, 
Diffusion based 
released
Antioxidant 
activity and 
sustained 
release
[14]
Lipid-polymer 
hybrid
Erlotinib, single-step sonication method, 
polycaprolactone (PCL), hydrogenated 
soy phosphatidylcholine, 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-
N-methoxy(polyethylene glycol)-2000 
(DSPE-PEG2000)
159.6–173 nm, PDI 
0.09–0.14
−1.22 to −47.3 18.1–66.4% 50% in first 3 h, 
100% in 24 h
Anticancer, 
lung cancer
[19]
PLGA, paclitaxel, PVA 200–300 nm 34.8 ± 1.6 to 
62.6 ± 7.9%
Fast release in 
first 3 days (60%) 
followed by 
slow first order 
release for 21 days 
(cumulative release 
72%)
Anticancer [22]
Lipid-polymer 
hybrid
Doxorubicin, stearic acid, tristearin, 
HPESO (hydrolyzed polymer of 
epoxidized soybean oil), Pluronic-F68
290 nm 5% Anticancer [30]
Lipid vesicles Carboxymethyl chitosan, paclitaxel, 
1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine 
(DPPC)
200–300 nm 85.2 ± 3.3 and 
83.8 ± 7.5%
Sustained release 
formulation
Anticancer [31]
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Type of 
hybrid 
nanoparticles
Structural components Physicochemical properties Biological 
properties
Application Reference
Size (nm) Zeta potential Entrapment 
efficiency
Lipid-polymer 
hybrid
Doxorubicin, epoxidized soyabean oil, 
Pluronic F68
80–350 nm −19.7 ± 0.65 60–80% 50% drug released 
in first few hours 
and additional 
10–20% in 2 weeks
Anticancer 
(breast cancer)
[32]
Lipid-polymer 
hybrid
Mitoxantrone hydrochloride, dextran 
sulfate, Cremophor (polyethoxylated 
castor oil), emulsification-
ultrasonication method
130.3 ± 4.7 to 
136.7 ± 8.6
−19.9 ± 1.4 to 
−31.6 ± 0.8
97.4% Sustained 86.9% 
at 72 h, Cmax (ng/
mL) 421.6 ± 24.6, 
t1/2 (h) 8.49 ± 1.23, 
AUC0-t (ng/mL.h) 
690.9 ± 83.5, 
AUC0-∞ (ng/mL.h) 
722.6 ± 94.1
Anticancer [33]
Sorafenib, PLGA, Single-step 
nanoprecipitation, D-α-tocopherol 
polyethylene glycol 1000 succinate, 
TPGS, dioleoylphosphatidic acid 
(DOPA)
150–200 nm (average 
175.25 ± 1.82 nm), PDI 
0.148 ± 0.004
−19 to −55 85% Highly vascular 
hepatocellular 
carcinoma
[34]
Mitomycin C, PLA, Soybean 
phosphatidylcholine (SPC), PEG, folate
215.6 ± 5.1 nm, PDI 
0.143
−25.88 ± 2.39 95% Anticancer [35]
Lipid-polymer 
hybrid
Paclitaxel, PLGA, 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine 
(DSPE), 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine (DSPE-
PEG-2000), folic acid, soybean lecithin
74.93 ± 3.93 to 
81.34 ± 3.41%
87.2 ± 4.28 to 
96.9 ± 4.93% in 
5 days
Anticancer [36]
Lipid-polymer 
hybrid
Nanoprecipitation process, PLGA, PEG, 
docetaxel
25 nm −10 to −50 20% 50% in first 12 h and 
remaining in 72 h
Anticancer [37]
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Type of 
hybrid 
nanoparticles
Structural components Physicochemical properties Biological 
properties
Application Reference
Size (nm) Zeta potential Entrapment 
efficiency
PLGA, Curcumin, 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine 
(DPPC), 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-
[succinyl(polyethylene glycol)-2000] 
(DSPE-PEG), emulsion/solvent 
evaporation technique
150 nm, 171.6 ± 8.2 nm 
in DI water and 
177.3 ± 6.2 nm in PBS, 
PDI of 0.174 ± 0.023 
and 0.159 ± 0.026
12% 30% in first 5 h Anticancer [38]
Lipid-polymer 
hybrid
Poly(ethylene glycol)-distearoylphos
phatidylethanolamine (PEG-DSPE), 
emulsifying-solvent evaporation 
method, egg yolk phosphatidylcholine, 
plasmid DNA
128 nm +35.2 Nonviral gene 
delivery
[39]
Poly-(β-amino ester) (PBAE), double 
emulsion/solvent evaporation, PLGA, 
Phospholipids
230 ± 40 to 300 ± 50, 
PDI 0.100 ± 0.05 to 
0.182 ± 0.10
32 ± 8 to 42 ± 8 mRNA based 
vaccine
[40]
Lipid-polymer 
hybrid
siRNA, PLGA, PEG, modified double-
emulsion solvent evaporation technique, 
lecithin
225 ± 8 nm −10 to 0 mV 78–82% 50% of siRNA 
released in 12–20 h
[41]
Lipid-polymer 
hybrid
PLGA, siRNA, Particle Replication in 
Nonwetting Templates (PRINT) process
198 ± 3.45 to 
207 ± 4.461, PDI 
0.045 ± 0.009 to 
0.092 ± 0.005
−3.45 ± 1.9 to 
5.29 ± 1.5
32–46% Prostate cancer [42]
Lipid-polymer 
hybrid
Norfloxacin, PLA, emulsification solvent 
evaporation method, PVA, carbopol 
K-940
178.6 ± 3.7 nm to 
220.8 ± 0.66 nm, 
PDI 0.206 ± 0.36 to 
0.383 ± 0.66
+23.4 ± 1.5 mV 
to 
+41.5 ± 3.4 mV
53.29 ± 0.30 to 
72.34 ± 0.23
89.72% drug 
released in 24 h
Topical 
antibiotic
[43]
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nanoparticles
Structural components Physicochemical properties Biological 
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Application Reference
Size (nm) Zeta potential Entrapment 
efficiency
Lipid-polymer 
hybrid
Lidocaine, Chitosan, Cholesterol, 
cetyltrimethyl ammonium bromide, 
1,2-dilauroyl-sn-glycero-3-
phosphocholine (DLPC), hyaluronic acid
71.2 ± 2.8 to 
145.6 ± 5.9 nm, 
PDI 0.09 ± 0.02 to 
0.19 ± 0.02
−4.6 ± 0.7 to 
+32.7 ± 4.6
78.6 ± 4.3 to 
85.2 ± 3.1
40% in 8 h and 
remaining in 72 h
Local anesthetic 
therapy
[44]
Lipid-polymer 
hybrid
Tenofovir disoproxil fumarate, melt 
emulsification-probe sonication 
technique
239 nm −42.1 ± 2.46 to 
−55.39 ± 3.12
87.14%, 63.83
±3.74 to 
90.84 ± 5.73%
85.34 ± 5% at the 
end of 12 h
Antiviral [45]
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roughing. These results indicated that Dox-PLN expressed a good cytotoxic activity 
against solid tumors and improved the therapeutic efficacy [30].
Paclitaxel loaded LPNs were prepared with a size range of 200–300 nm for oral 
administration. Theses LPNs were designed to withstand harsh gastrointestinal 
tract conditions and improve the bioavailability of paclitaxel. On comparison with 
Taxol, 1.5- and 5.5-fold increase in bioavailability and elimination half-life was 
observed, respectively. Additionally, reduction in the reticuloendothelial system 
mediated uptake by liver and spleen was noted due to stealth characteristics of 
biopolymer blanket of these LPNs [31].
To overcome the multidrug resistance (MDR) of anticancer drugs, a new strat-
egy was adopted in which doxorubicin loaded solid lipid nanoparticles (SLNs) were 
complexed with anionic polymer. Due to high encapsulation efficiency (60–80%) 
of doxorubicin, the cytotoxicity in tumor cells was increased to 8-fold. Due to 
physical interaction between drug and polymer and smaller size of nanoparticles 
(80–350 nm), drug was difficult to clear from target cells by efflux pump [32]. 
Another strategy to counter MDR is to synthesize lipid-anionic dextran sulfate 
hybrid carriers loaded with mitoxantrone hydrochloride. The interaction between 
cationic drug (mitoxantrone hydrochloride) and anionic dextran not only increased 
drug accumulation but also enhanced the cytotoxicity in breast cancer cell lines. 
Sustained release of drug (86.9%) was maintained for 72 h with an encapsulation 
efficiency of 97.4% [33].
Sorafenib is an antiangiogenic agent used in highly vascular hepatocellular car-
cinoma (HCC). The development of resistance during HCC therapy is mainly due 
to activation of CXC receptor type 4 (CXCR4). Gao et al. developed PLGA nanopar-
ticles loaded with sorafenib and evaluated the antitumor activity both in vitro and 
in vivo. On comparing with control group, sorafenib loaded PLGA nanoparticles 
have shown an improved survival in HCC model, delay in progression of tumor and 
enhanced antiangiogenic effect [34].
Mitomycin C is a water soluble drug and major disadvantages associated with 
this drug are poor water stability, rapid elimination and lacking in target specific-
ity. A sustained (up to 120 h) and effective delivery of mitomycin C from LPH 
Figure 2. 
Applications of lipid-polymer hybrid nanocarriers [46].
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nanoparticles was observed with improved encapsulation efficiency of 95%. 
Improved cell uptake and site specific accumulation of drug are the major advan-
tages of LPNs [35]. Paclitaxel and folic acid loaded polymer-lipid hybrid nanopar-
ticles were prepared to bypass the tight junctions of blood-brain barrier (BBB) 
and target the glioma cells. The survival time of mice was increased to 42 days as 
compared to free paclitaxel which last only 18 days. These targeted nanoparticles 
have shown better pharmacokinetics and biodistributions which result in better 
therapeutic outcomes [36].
Ultra-small lipid-polymer hybrid nanoparticles were fabricated using modified 
nanoprecipitation method. The prepared nanoparticles loaded with docetaxel have 
the size of 25 nm which exhibited a better antitumor activity than Taxotere. It was 
observed that the survival time of Taxotere treated mice were 44 days whereas 
more than half of the mice treated with ultra-small nanoparticles survived for 
64 days. These ultra-small nanoparticles have better biodistribution properties and 
enhanced permeation ability [37]. Long circulating PLGA nanoparticles loaded 
with curcumin were fabricated to counter cancer metastasis. The adhesion of cancer 
cells onto endothelial cells and vascular deposition were reduced by 70 and 50%, 
respectively. Therefore, these nanoparticles could improve the therapeutic efficacy 
by preventing metastasis and impairing circulating tumor cells [38].
Core-shell LPN was fabricated to deliver erlotinib using single-step sonication 
method. In vitro cellular uptake, colony forming assay and luminescent cell viability 
assay was performed in human lung adenocarcinoma cell line (Figure 3). The mean 
particle size of LPN is 170 nm and entrapment efficiency of 66% with excellent 
storage stability. The enhanced and efficient uptake of these LPN by cancer cells 
makes these nanoparticles a potential delivery system for erlotinib [19].
Figure 3. 
(A) Confocal microscopy images of erlotinib loaded CSLPHNPs uptake in A549 cells after 1 and 4 h, (B) 
in vitro cellular viability result in A549 cells after 72 h, and (C) colony formation assay in A549 cells [19].
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4.2 Gene delivery
Plasmid DNA, miRNA and siRNA are now gaining much of the interest of 
researchers for cancer therapy. Both miRNA and siRNA have different origin and 
mechanism but similar physicochemical properties. miRNA is endogenous in nature 
and target the mRNA by developing imperfect pairing and hence act by mRNA deg-
radation, mRNA endonucleolytic cleavage or suppression of translation. siRNA is 
exogenous in nature and primarily act by endonucleolytic cleavage of target mRNA. 
siRNA has single mRNA target whereas miRNA has multiple targets. Plasmid DNA 
carries the recombinant gene or gene of interest and can be administered locally of 
systemically for cancer therapy [47–50].
Lot of challenges is associated with effective gene delivery especially for cancer 
therapy. Viral vectors are also facing problems such as development of immunity 
and inflammatory response, limited carrying ability of DNA and short shelf 
life [51]. Therefore, the research has now been shifted to nonviral vectors due to 
nonimmunogenicity, nontoxicity, low cost and feasibility in large scale production. 
Polyethylene glycol (PEG) and its copolymers have widely used for gene delivery 
because of its low toxicity, increase water solubility and reduced ability to interact 
with serum proteins [52].
Effective gene delivery through nonviral vectors with reduced toxicity was developed 
by emulsification solvent evaporation method. The particle size of newly developed 
positively charged LPN is in the range from 130 to 240 nm. Fluorescent protein was 
complexed with plasmid DNA by adsorption and transfection efficiencies was recorded 
as 37.2 and 34% for LPN and commercially available product, respectively [39].
Core shell LPN was fabricated using three different methods for incorporation of 
DNA and the resulted nanoparticles were in the range from 100 to 400 nm. Surface 
adsorbed DNA, encapsulated DNA and combination of adsorbed and encapsulated 
DNA are three important methods for fabrication of these nanoparticles. For sus-
tained release of active ingredient, combination method is employed which is neces-
sary for booster vaccination followed by decline release. For primary vaccination 
(strong and short effective delivery), surface adsorbed mechanism is followed. By 
adjusting the concentration of different ingredients, the drug release properties can 
be adjusted [53].
SiRNA delivery through cationic complexes such as polyplexes and lipoplexes 
has many disadvantages, e.g., development of inflammatory responses, instability 
and toxicity etc. Small size (100 nm) with prolong circulation time nanoparticles 
containing siRNA was developed using PLGA. These hybrid nanoparticles has 80% 
encapsulation efficiency of siRNA without any significant degradation until 24 h. 
Immunofluorescence studies revealed the in vitro apoptosis and >90% knockdown 
of nonsmall cell lung cancer [54].
LPNs are also used for incorporation of mRNA for mRNA vaccines. mRNA was 
complexed with LPN through electrostatic adsorption to develop 150–300 nm size 
nanoparticles. These newly developed nanoparticles have shown successful transfection 
through intranasal route and taken up by dendritic cells with minimum toxicity [40].
A novel approach, modified double emulsion/solvent evaporation method, 
was used to fabricate hollow core/shell LPNs in which PLGA core was surrounded 
by lipid shell attached with PEG chains. The size of nanoparticles was 230 nm, 
80% encapsulation efficiency and 50% siRNA was sustained release for 12–20 h. 
Moreover, enhanced gene silencing ability was also observed with profound inhibi-
tion of gene expression in xenograft tumor [41]. PLGA/siRNA nanoparticles coated 
with lipids are prepared using Particle Replication in Non wetting Templates tech-
nique and exhibited 32–46% encapsulation efficiency for the treatment of prostate 
cancer [42]. siRNA was localized in PLGA core at high concentration by varying the 
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concentration of polymer and lipid. This localized siRNA then modifies the release, 
physicochemical properties and transfection efficiencies [55].
4.3 Theranostic agents
LPNs not only used for delivering of therapeutic agent but also used for diagnostic 
purpose. Different type of imaging agents such as quantum dots, fluorescent dyes 
and iron oxide are incorporated in polymer core. Lipid-polymer and lipid-quantum 
dot nanoparticles were prepared in a single step with narrow size distribution [56]. 
Physicochemical properties can be controlled by varying the experimental conditions. 
Such multicomponent nanoparticles can be used therapy and diagnosis simultaneously.
LPNs are used for theranostic purposes in which phospholipids are attached on 
one side of polymer chain and fluorophores are linked on the other side. LPNs were 
designed to incorporate MRI contrast agent, gadolinium, chelated with lipid-PEG 
in PLGA core. These agents have shown effective uptake of nanoparticles within 
3 h by J-774 cells [57]. Instead of conjugation with imaging agent, fluorescence 
dye was uploaded in LPNs core surrounded by lipid-PEG shell. The final size of 
such nanoparticles was in the range from 20 to 30 nm and bright fluorescence was 
observed due to lipid tail and polymeric core [58].
4.4 Stimuli responsive LPNs
Stimuli responsive drug delivery systems have the ability to deliver therapeutic 
agents at target sites in a controlled manner with minimum side effects. LPNs com-
prise of magnetic beads. Stimuli responsive drug delivery system has the advantage 
to deliver the therapeutic agent in a controlled manner at target site. In a core (PLGA) 
shell (soyabean lecithin) nanoparticle system, magnetic beads were used for stimuli 
responsive release of camptothecin when exposed to radio frequency magnetic field. 
The release of drug was increased by 60% using radio frequency which significantly 
decreased the mouse breast cancer cell growth. Such system can be beneficial in cancer 
chemotherapy due to easy preparation, bio-stability and site specific drug delivery [59].
4.5 Miscellaneous pharmacological applications
Hepatitis C is a chronic disease which leads to liver cirrhosis and hepatocellular 
carcinoma. LPNs are used to label HCV viral particles for their detection, possible 
interaction and entrance pathway into host cells [60].
SLNs are developed for topical administration of norfloxacin using solvent 
evaporation method. These nanoparticles have shown antimicrobial activity against 
Staphylococcus aureus and Pseudomonas aeruginosa and could be used for the treat-
ment of burn wound and topical infections. SLNs have shown 89.72% drug release 
after 24 h and passed the skin irritation and stability tests [43].
LPNs have recently used for improving the local anesthetic action of lidocaine. 
Two different kinds of nanocarriers, i.e., liposomes and LPNs were prepared and 
evaluated the skin permeation ability, in vitro and in vivo drug release studies, 
encapsulation efficiency and particle size. Results indicated that LPNs has better 
and improved efficacy of lidocaine as compared to liposomal delivery system due to 
smaller size (88.6 nm). The steady state flux of LPNs was found to be 65.4 μg/h/cm2 
which showed increased skin permeation capacity [44].
LPNs were used for nasal delivery of an antiviral drug, tenofovir using melt 
emulsification-probe sonication technique. Intranasal flux of 135.36 μg/cm2/h and 
enhanced fluidity improved the drug permeation through membrane phospholip-
ids, which increase the bioavailability of the drug [45].
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